A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy

Taejoon Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Bowel Preparation

Treatments: Drug: Conventional OST; Drug: CTP0302-A; Drug: CTP0302-B

Study type: Interventional

Funder types: Industry

Identifiers

NCT06287606

CTP0302

Details and patient eligibility

About

A prospective randomized study compared to the active control. Researchers compare colon cleansing in patients undergoing colonoscopy

Full description

This is a prospective randomized study compared with active control arm. The investigators compare the colon cleansing in patients undergoing colonoscopy.

Enrollment: 161 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients must provide written informed consent.
• Male and female outpatients and inpatients aged: ≥19
• Patients BMI shoule be ≤ 30

Exclusion criteria

• Patients with past history of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
• Patients with ongoing severe acute Inflammatory Bowel Disease.
• Patients who have had previous significant gastrointestinal surgeries, including colonic resection, subtotal colectomy, abdominoperineal resection, defunctioning colostomy.
• Pregnant women or pregnant women or pregnant women
• Severe heart disease (cardiac failure (NYHA class 3 and 4))
• Acute coronary artery disease within 24 weeks before screening (an unstable angina pectoris, acute myocardial infarction), clinically significant arrhythmia, hypertrophic obstruction Cardiomyopathy, valvular disease, aortic and peripheral vascular diseases.
• People who have hypersensitivity or allergies to clinical trial drug components.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

161 participants in 3 patient groups

CTP0302-A

Experimental group

Description:

2 days split-dose

Treatment:

Drug: CTP0302-A

CTP0302-B

Experimental group

Description:

One day dose

Treatment:

Drug: CTP0302-B

Conventional OST

Active Comparator group

Description:

2 days split-dose

Treatment:

Drug: Conventional OST